Cooley - Latest News and Information
Technology Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
On March 17, 2026 the CFTC’s Market Participants Division issued a no‑action letter to Phantom Technologies, a self‑custodial crypto‑wallet provider, stating it will not enforce IB registration requirements. Phantom plans to let users access CFTC‑regulated derivatives through third‑party collaborators while retaining no custody or order‑routing discretion. The relief is conditioned on joint liability undertakings, comprehensive user disclosures, and compliance‑like policies. This framework creates a regulatory pathway for non‑custodial wallets to integrate derivatives trading without becoming registered brokers.
Neurocrine Biosciences announced a $2.9 billion cash deal to acquire Soleno Therapeutics, a company focused on novel rare‑disease treatments. The transaction broadens Neurocrine’s endocrinology and rare‑disease pipeline, adding late‑stage candidates and commercial assets. Cooley LLP, Neurocrine’s long‑time corporate counsel, led the...
The FDA released its first draft guidance outlining how drug, biologic and veterinary manufacturers should respond to Form FDA 483 observations. The document mandates a structured response—including an executive summary, risk assessments, and detailed remediation plans—and requires identification of the...
Rachel Proffitt, Cooley’s partner and CEO, sat down on the Drinks With The Deal podcast to outline her leadership philosophy for navigating rapid change. She highlighted the importance of flexible organizational structures, proactive talent management, and the strategic use of...
The U.S. Center for Devices and Radiological Health (CDRH) is grappling with heavy workloads after a year of staff reductions, according to Cooley counsel Son Nguyen. Remaining reviewers report heightened case volumes and frequent mid‑application decision changes, creating uncertainty for...
Michael Attanasio, a Cooley partner, was named by the Daily Journal as one of California’s Leading Commercial Litigators. The accolade highlights his role in high‑stakes cases, notably securing a temporary restraining order, a permanent injunction, and summary judgment against a...
Korsana Biosciences announced a merger with Cyclerion Therapeutics, accompanied by a $380 million private placement. The financing round was led by Fairmount and Venrock Healthcare Capital, with participation from a slate of prominent venture and institutional investors. Cooley LLP represented the...
New York’s amended Responsible AI Safety and Education (RAISE) Act, signed on March 27, 2026, aligns closely with California’s Transparency in Frontier Artificial Intelligence Act (TFAIA) by adopting the same frontier‑AI framework and transparency‑report requirements. The law revises key definitions,...
Cooley has been shortlisted for seven Asian Legal Business China Law Awards in 2026, covering firm‑wide, deal‑specific and individual categories. The firm earned nominations for International Law Firm of the Year, International Deal Firm of the Year, Capital Markets Law...
Cooley’s global M&A and private‑equity practices retained top positions in Bloomberg’s Q1 2026 league tables. The firm ranked #1 worldwide in both life‑science and technology deal counts, #3 overall M&A, and #2 in private‑equity transactions. It advised on high‑profile deals...
The U.S. Securities and Exchange Commission has withdrawn its longstanding Rule 14a‑8 no‑action process, removing the informal guidance companies relied on for shareholder proxy proposals. In response, investors are filing lawsuits challenging the validity of certain proxy proposals under the new...
Geron Corporation and its officers secured a dismissal without prejudice of a federal securities‑fraud class action tied to the launch of its blood‑cancer drug RYTELO. U.S. District Judge Vince Chhabria ruled the plaintiffs failed to allege a plausible intent to...
